1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
MEDINET Co., Ltd.

MEDINET Co., Ltd.

TTSE:2370
22.00
JPY
0.00
(0.00%)
8.05BMarket Cap
Nov 12Next Earn
MEDINET Co., Ltd.
TSE:2370
(Tokyo Stock Exchange)

Recent

price

22.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
50.66
37.43
29.9
26.14
20.93
18.85
20.93
17.83
8.41
8.94
5.76
3.96
3.2
3.06
3.03
3.06
- -
Revenue per Share
6.94
-7.59
-8.53
-4.32
-17.94
-19.28
-18.01
-27.24
-27.47
-6.71
-6.19
-4.88
-6.33
-6.65
-5.04
-5.15
- -
Basic EPS, GAAP
6.69
-5.74
-7.78
-7.77
-18.14
-28.63
-12.56
-14.17
-23.92
-8.83
-4.8
-5.84
-6.07
-6.24
-5.25
-5.46
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
60.93
74.87
67.17
118.74
95.99
79.59
64
50.59
27.49
21.43
29.89
27.43
26.03
21.73
19.62
14.27
12.89
Book Value per Share
59.88
72.01
63.76
115.8
92.69
76.03
61.14
49.69
26.82
20.96
29.67
27.16
25.55
21.24
19.24
14.01
12.55
Tangible Book Value per Share
63
71
73
81
88
89
91
96
114
118
136
173
198
216
253
265
267
Basic Weighted Avg Shares
3,202
2,674
2,191
2,110
1,844
1,674
1,909
1,704
958
1,059
783
683
634
662
769
810
- -
Sales/Revenue/Turnover
10.43
-11.35
-32.46
-41.6
-76.3
-104.03
-88.05
-105.72
-283.39
-95.21
-118.27
-158.21
-210.38
-215.55
-180.19
-178.39
- -
Operating Margin (%)
129
154
212
211
195
278
357
320
193
207
155
115
106
103
115
102
- -
Depreciation Expense
439
-543
-625
-348
-1,581
-1,712
-1,643
-2,604
-3,128
-795
-842
-843
-1,254
-1,438
-1,277
-1,362
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
13.69
-20.29
-28.53
-16.51
-85.72
-102.27
-86.06
-152.8
-326.57
-75.1
-107.53
-123.48
-197.91
-217.36
-166.17
-168.1
- -
Profit Margin (%)
2,944
4,387
3,196
7,149
5,310
3,414
3,066
3,665
2,078
1,524
3,660
4,130
4,528
4,422
4,744
3,379
3,201
Working Capital
1,021
1,050
1,035
48
50
144
182
73
29
12
8
4
2
1
- -
- -
- -
LT Debt
3,855
5,486
4,922
10,370
8,479
7,173
5,931
5,480
3,251
2,590
4,807
4,903
5,512
5,044
5,191
3,778
3,575
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
12.23
-11.62
-12.01
-4.56
-16.77
-21.88
-25.08
-45.63
-71.66
-27.23
-22.77
-17.37
-24.08
-27.24
-24.95
-30.38
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Dec'24
Mar'24
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
254
256
277
Market Capitalization
10,901
13,322
8,045

Working Capital

JPY

•

in mil. unless spec.
Dec'24
Mar'24
Mar'26
Total Current Assets
5,394
5,207
3,440
Cash, Cash Equivalents & STI
5,033
4,901
2,928
Accounts Receivable, Net
225
204
336
Inventories
49
52
82
Total Current Liabilities
273
257
239
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.88%
-3.68%
-27.23%
Free Cash Flow
5.84%
18.63%
8.66%
Net Income, GAAP
6.49%
11.8%
6.67%
Sales/Revenue/Turnover
-5%
1.2%
5.44%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
248
151
- -
- -
769
2025
- -
- -
- -
- -
810
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.2
-1.34
- -
- -
-5.04
2025
- -
- -
- -
- -
-5.15
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
MEDINET Co., Ltd. (2370.T) engages primarily in the cell processing industry and cellular medical products business as a contract development and manufacturing organization providing comprehensive regenerative medicine and cell therapy solutions in Japan. The company offers manufacturing of regenerative medical products, investigational products, and specified cell products encompassing somatic cells such as CAR-T and immuno-cells including NKT cells-activated dendritic cells, dendritic cells, NK-cells, gamma delta T-cells, alpha beta T-cells; somatic stem cells like endometrium, mesenchymal stem cells, hematopoietic stem cells; and induced pluripotent stem cells; alongside value chain solutions comprising personnel training, facility and equipment design, operations and management, standard operating procedures preparation, logistics network, information systems, purchasing and production management, quality management systems, quality control and assurance, technology transfer, and process development. Founded in 1995 and headquartered in Tokyo, MEDINET operates from its Shinagawa Cell Processing Facility and supports medical institutions, research institutions, and biopharmaceutical companies primarily in Japan with expertise in therapies such as NKT-cell therapy, dendritic cell vaccine therapy, NK-cell therapy, gamma delta T-cell therapy, alpha beta T-cell therapy, and CTL therapy. Recent developments include a strategic partnership with AGC Inc. in September 2024 to accelerate cell and gene therapy CDMO business in Japan; a licensing agreement with Stempeutics Research Pvt. Ltd. in October 2025 for the Stempeucel cell therapy targeting chronic thromboembolic pulmonary hypertension; initiation of NKT cell-activated dendritic cell processing technology provision in February 2023; and a market transition from Tokyo Stock Exchange Mothers to Growth in April 2022.